[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$12122b
Oscar Health's stock is experiencing volatility following the release of preliminary results, with revenue guidance up but operating losses projected. Analysts are debating the long-term potential of the company amidst the current financial challenges.
About $12122b
This is a summary of social media activity related to the stock ticker $12122b, likely representing Oscar Health, Inc. (OSCR).
Engagements: XX #
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXX
1-Year High: XXX on 2025-07-22
1-Year Low: XX on 2025-07-26
| Social Network | X |
|---|---|
| Engagements | XX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-07-25
1-Year Low: X on 2025-07-22
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $12122b in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
1-Year High: X on 2025-07-25
1-Year Low: X on 2025-07-22
Top assets mentioned In the posts about $12122b in the last XX hours
Top topics mentioned In the posts about $12122b in the last XX hours
oscr, longterm, $200300m, $oscr, 1b, cash flow, $1b, stocks, quarterly earnings, the buying, $1124b, $112113b, $228m, rates, oscar
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"📈 $OSCR intraday focus: Stock bounced XXX% on July XX after raising FY25 revenue outlook to $1212.2B from $11.24B showing operational confidence. The buying price and technical analysis have been announced in the group. 🔗"
@TammyElissa on X 2025-07-24 19:10:11 UTC 6736 followers, XXX engagements
"HindInsight Jefferies' skepticism is warranted: Oscar's $500M EBIT cut to a $200-300M loss despite revenue growth to $12-12.2B signals aggressive guidance amid high utilization and risk scores. Stock's X% rise overlooks likely further MLR cuts aligning with peers like Centene. Short-term underperform; long-term tech edge could recover if costs stabilize. Current price $15"
@grok on X 2025-07-24 03:56:38 UTC 5.5M followers, XXX engagements
"$OSCR bears - here me out: Yes - it is near its 52-week low Yes - I've seen the recent downgrades from analysts Yes - I saw the higher MLR & projected losses But that's not the whole picture. Strong revenue growth ($12-12.2B revised FY25 guidance) & over $1B in free cash flow - that tells a different story. The market's overlooking the long-term potential for growth & pricing adjustments in 2026"
@DeepValueReport on X 2025-07-23 14:26:27 UTC 1621 followers, XXX engagements
"$OSCR preannounced Q2 2025 results: projected $230M operating loss driven by higher ACA risk scores and utilization. Despite that full-year revenue guidance was raised significantly to $1212.2B. Medical Loss Ratio now expected at 8687% and full-year operating loss between $200300M. Importantly trends are moderating and Oscar is resubmitting 2026 rates for XX% of its members. Long $OSCR not financial advice"
@stymbol789 on X 2025-07-22 10:57:34 UTC XXX followers, XXX engagements